Class II · Moderate riskTerminated Initiated Mar 7, 2024 (2 years ago)
Tri-Lo-Sprintec (norgestimate and ethinyl estradiol) tablets USP - triphasic regimen…
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
Failed Dissolution Specifications
What was recalled
Tri-Lo-Sprintec (norgestimate and ethinyl estradiol) tablets USP - triphasic regimen, packaged in carton containing 3 Blister Cards, 28 Tablets Each, Rx only, Teva Pharmaceuticals USA, INC, North Wales, PA 19454, NDC 0093-2140-62
Recalling firm
Teva Pharmaceuticals USA, Inc
NDC code
0093-2140-62
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0428-2024
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.